Efficacy and safety of latanoprost/timolol fixed combination dosed twice daily compared to once daily in patients with primary open angle glaucoma

AIM:To evaluate whether latanoprost/timolol fixed combination(LTFC)dosed twice daily may provide further intraocular pressure(IOP)reduction and evaluate the safety profile at this dose.METHODS:This is an open-labeled,randomized,prospective crossover study on fourty primary open angle glaucoma patients.Two weeks of washout period were followed by randomization to either once daily(OD,group A)or twice daily dosing(BD,group B)of LTFC for 4wk.After another 2-week washout period,the patients’treatment dose was crossed-over for another 4wk.IOP reduction alongside ocular and systemic side effects were evaluated.RESULTS:Mean baseline IOP was 18.57±2.93 and 17.8±3.01 mm Hg before OD and BD dose respectively,(P=0.27).Mean IOP after BD dose was statistically lower(12.49±1.59 mm Hg)compared to OD(13.48±1.81 mm Hg,P=0.017).Although IOP reduction after BD dose was more(5.32±3.24 mm Hg,29.89%)than after OD dosing(5.04 mm Hg,27.14%),it did not reach statistical significance(P=0.68).Patients switched from OD to BD(group A)showed mean IOP reduction by 0.69 mm Hg[95%confidence interval(CI):-0.09 to 1.48 mm Hg,P=0.078];but patients switched from BD to OD(group B)had significantly higher mean IOP by 1.25 mm Hg(95%CI:-2.04 to-0.46 mm Hg,P=0.006).BD dose had more ocular side effects albeit mild.CONCLUSION:Mean IOP after LTFC dosed twice daily is statistically lower,with additional mild side effects.

Effect of long-term topical latanoprost medication on conjunctival thickness in patients with glaucoma

AIM： To investigate the effect of long-term use of topically administered latanoprost on conjunctival thickness（CT） and conjunctival epithelium thickness（CET） in the patients with glaucoma. METHODS： A series of 106 glaucomatous patients were included. Of the 106 eyes, 55 eyes were treated with latanoprost eye drops once a day（latanoprost group）, while 51 eyes were treated with carteolol hydrochloride eye drops（carteolol group）. All the included patients completed a 2-year follow-up. CT and CET were measured with optical coherence tomography（OCT） in all patients at presentation and at 2-year visit, respectively. Statistical analysis was then performed to compare the change in CT and CET. RESULTS： At presentation, there was no difference in CET（t=0.400, P=0.689） or CT（t=1.14, P=0.259） between the two groups. No significant difference was found in CET（61.65±5.35 μm at baseline, 60.36±6.36 μm at 2-year follow-up, respectively; t=1.977, P=0.0531）, while there was a significant decrease in CT from 201.45±14.99 μm at baseline to 167.81±14.57 μm at 2-year visit（t=14.1407, P〈0.001） in the latanoprost group. At 2-year follow-up, no statistically difference was found in CET（62.24±5.27 μm; t=1.086, P=0.282） or CT（201.23±12.45 μm; t=1.44, P=0.154） compared to it at baseline（CET： 61.23±5.42 μm; CT： 198.76±13.68 μm, respectively） in the carteolol group. CONCLUSION： A significant decrease in conjunctival thickness is found in glaucoma patients treated with long-term topical latanoprost; its potential effect on the outcome of filtration surgery should be considered.

Fixed combination of latanoprost and timolol vs the individual components for primary open angle glaucoma and ocular hypertension:a systematic review and meta-analysis

AIM:To assess the effects of the fixed combination of0.005% latanoprost and 0.5% timolol(FCLT) vs their individual components for primary open angle glaucoma(POAG) and ocular hypertension(OHT).· METHODS:After searched PubMed, EMBASE, the Cochrane Library and SCI, all randomized controlled clinical trials(RCTs) and cross-over studies were included. The control groups were the monotherapy or the concomitant therapy of latanoprost and timolol. The outcomes were visual field defect, optic atrophy, mean intraocular pressure(IOP) and IOP fluctuation. The analysis was carried out in RevMan version 5.1 software.RESULTS:Thepost-interventionmeanIOPofFCLTwas significantly lower compared to timolol [mean difference(MD)-2.92, 95%CI-3.28 to-2.55, P 【0.00001] and latanoprost(MD-1.11, 95%CI-1.51 to-0.72, P 【0.00001). The postintervention IOP fluctuation was also significantly lower compared to timolol(MD-0.88, 95%CI-1.23 to-0.53, P 【0. 00001) and latanoprost( MD- 0. 63, 95 % CI- 1. 04to-0.22, P =0.002). The mean IOP was higher in FCLT morning dose group than the one in unfixed combination of 0.005% latanoprost and 0.5% timolol(UFCLT)(MD1.10, 95% CI 0.81 to 1.39, P 【0.00001). Otherwise, there was no difference between FCLT evening dose group and UFCLT(MD 0.34, 95% CI-0.01 to 0.69, P =0.06).There was no statistical difference for the incidence ofvisual field defect and optic atrophy between FCLT and the monotherapy of components.CONCLUSION:A better IOP lowering effect has been demonstrated for FCLT compared to the monotherapy of components. The IOP lowering effect was worse for FCLT morning dose and almost same for FCLT evening dose compared to the UFCLT. We need more long-term high quality RCTs to demonstrate the outcomes of visual field defect and optic atrophy.visual field defect and optic atrophy between FCLT and the monotherapy of components.CONCLUSION:A better IOP lowering effect has been demonstrated for FCLT compared to the monotherapy of components. The IOP lowering effect was worse for FCLT morning dose and almost same for FCLT evening dose compared to the UFCLT. We need more long-term high quality RCTs to demonstrate the outcomes of visual field defect and optic atrophy.

Efficacy and safety of 0.0015% tafluprost versus 0.005% latanoprost in primary open angle glaucoma, ocular hypertension: a Meta-analysis

AIM:To evaluate the intraocular pressure(IOP)-lowering efficacy and safety of tafluprost 0.0015%eye drops[benzalkonium chloride(BAK)0.1 mg/mL]compared with that of latanoprost 0.005%eye drops(BAK 0.2 mg/mL)for primary open angle glaucoma(POAG)and ocular hypertension(OHT).METHODS:All the randomized controlled trials(RCTs)about treating POAG and OHT comparing tafluprost and latanoprost were collected by searching PubMed,Embase,Cochrane Library,CNKI and VIP.The outcomes of interest to evaluate the clinical efficacy and adverse effects included IOP and patient-related drop discomfort.RESULTS:Five RCTs involving 888 glaucoma patients were included.The results showed that,1)at the end of the study,no statistically significant differences were observed in IOP reduction[standard mean difference(SMD)=0.48,95%CI 0.07 to 0.88,P=0.085]between tafluprost and latanoprost;2)No statistically significant differences were observed in adverse events of foreign-body sensation[relative risk(RR)=0.62,95%CI 0.26 to 1.46,P=0.269],eye irritation(RR=1.16,95%CI 0.49 to 2.75,P=0.744),eye pain(RR=2.000,95%CI 0.949 to 4.216,P=0.07),iris hyperpigmentation(RR=0.741,95%CI 0.235 to 2.334,P=0.61),dry eye(RR=1.154,95%CI 0.409 to 3.256,P=0.79)and eye pruritus(RR=1.600,95%CI 0.536 to 4.774,P=0.4)between tafluprost and latanoprost.However,tafluprost showed more reported incidence of conjunctival hyperaemia than latanoprost(RR=2.11,95%CI 1.24 to 3.59,P=0.006).CONCLUSION:Tafluprost 0.0015%eye drops(BAK 0.1 mg/mL)and latanoprost 0.005%eye drops(BAK 0.2 mg/mL)are comparable in lowering IOP for open angle glaucoma(OAG)and OHT.It does not differ in the incidence of foreign-body sensation,eye irritation,eye pain,iris hyper-pigmentation,dry eye and eye pruritus,but tafluprost shows less ocular tolerability because of more incidence of conjunctival hyperaemia.

Effect of latanoprost/timolol and dorzolamide/tiomolol on intraocular pressure after phacoemulsification surgery

·AIM:To evalaute the effect of fixed-combination latanoprost 0.005%/timolol maleate 0.5% and dorzolamide hydrochloride 2%/timolol maleate 0.5% on postoperative intraocular pressure after phacoemulsification cataract surgery.·METHODS:This study is a prospective,randomized,double-masked and placebo-controlled.The study included 90 eyes of 90 patients which were scheduled to have phacoemulsification surgery.Patients were randomly assigned preoperatively to 1 of 3 groups (30 eyes of 30 patients).Two hour before surgery,the patients received one drop latanoprost/timolol (group 1),dorzolamide/timolol (group 2) and placebo (group 3,control group).The IOPs were measured at preoperative and postoperative 4,8,and 24 hours.·RESULTS:The preoperative mean intraocular pressure was not statistically significant between both drug groups and control group.In group 1 and 2,the postoperative mean IOP [group1:(14.03?à3.15)mmHg and group 2:(14.16?à4.43)mmHg] at 24 hours were significantly lower than the control group [(16.93?à3.70)mmHg,(P <0.05)].In addition,the postoperative mean IOP of group 1 [(14.90±3.69)mmHg] at 8 hours was significantly lower than the control group [(17.70?à3.89)mmHg,(P <0.05)],but there was no significant difference between group 2 [(16.16?à5.23)mmHg] and control group at 8 hours (P >0.05).·CONCLUSION:When compared with placebo,the use of preoperative fixed combination of latanoprost/timolol and dorzolamide/timolol is an effective method for preventing intraocular pressure elevation in 24 hours after phacoemulsification surgery,but did not completely prevent IOP spikes.·

Long-term cost and efficacy analysis of latanoprost versus timolol in glaucoma patients in Germany

AIM: To evaluate 5-year effectiveness and cos between latanoprost or timolol monotherapy in a pilot trial.METHODS: A retrospective, multi-center trial performed at 6 sites in Germany of patients who had a diagnosis of primary open-angle or pigmentary glaucoma, in at least one eye, initiated on monotherapy with latanoprost or timolol maleate. Qualified consecutive charts were reviewed in which 5-year efficacy, safety and cost data was abstracted.RESULTS: Seventy-seven latanoprost and 49 timolo patients were included, at the final visit no difference existed between the two groups in disc parameters including: rim area, rim area/disc area ratio, cup volume or vertical cup/disc ratio (P 】0.05). There was no difference in intraocular pressure (IOP) between the initial latanoprost (17.4 ±2.6) and timolol (16.3 ±2.8mmHg) groups. There was less change in medicines over the follow-up period (0.1 vs 0.8) and fewer medications at the final visit (1.2 vs 1.8) with latanoprost compared to timolol. No patient treated with latanoprost discontinued therapy during follow-up, while 12% discontinued timolol mostly due to inadequate IOP control. Cost/year was less with initial timolol ($458±236) as compared to latanoprost ($552±202). CONCLUSION: Patients begun on latanoprost o timolol and followed over 5 years may have similar clinical outcomes. However, timolol patients may require more medicines and medicine changes to control IOP for long-term, but at a lower cost.

Efficacy and safety of newly developed preservative-free latanoprost 0.005% eye drops versus preserved latanoprost 0.005% in open angle glaucoma and ocular hypertension: 12-week results of a randomized,multicenter, controlled phase Ⅲ trial

AIM: To evaluate the therapeutic efficacy, safety and tolerability of newly developed preservative-free(PF) latanoprost generic [TJO-002] and compare it with benzalkonium chloride(BAK)-preserved latanoprost [Xalatan?] in patients with primary open angle glaucoma(POAG) and ocular hypertension(OHT).METHODS: Included patients were aged ≥19 y with POAG/OHT. After a washout period, patients with IOP 21-35 mm Hg at 9 a.m. were enrolled. After a full ophthalmic and glaucoma examination, 144 patients with POAG and OHT participated in this study. Subjects were randomly assigned either PF latanoprost(74 eyes) or BAK-preserved latanoprost(70 eyes). All subjects were examined at 4, 8, and 12 wk after first administration. At each follow-up visit,IOP was measured at 9 a.m. and 5 p.m. and compliance was assessed. Throughout the study, all adverse events were recorded and monitored by the masked investigators who measured IOP.RESULTS: Both groups showed a statistically significant decrease of average diurnal IOP at 12 wk compared to baseline(-7.21±3.10 mm Hg in the PF latanoprost group and-7.02±3.17 mm Hg in the BAK latanoprost group, both P<0.0001). There was no statistically significant diurnal IOP variation between the groups. In terms of tolerability, pruritus, burning/stinging, and sticky eye sensation, severity was significantly lower in the PF latanoprost group than in the BAK latanoprost group(P<0.05). CONCLUSION: PF latanoprost has at least similar efficacy in terms of IOP reduction and better tolerability compared with BAK latanoprost.

Latanoprost eye drops induce conjunctival lymphatic vessel development

AIM:To investigate the effect of latanoprost eye drops on the conjunctival lymphatics.METHODS:Twenty-four healthy New Zealand White rabbits weighing 1.5 to 2.0 kg were randomly divided into three groups:latanoprost group(n=8)administered with latanoprost eye drops once a day for 2 mo,carteolol group(n=8)administered with carteolol eye drops once a day for 2 mo,and control group(n=8)without any treatment.The conjunctival tissues in the three groups were extracted to investigate the expression levels of 5’-nucleotidase(5’-Nase)by Western blot,reverse transcription-polymerase chain reaction(RT-PCR),and immunofluorescence staining,respectively.RESULTS:The protein expression level of 5’-Nase was significantly higher in latanoprost group than carteolol group(F=231.175,P<0.001)and control group(P<0.001),while there was no significant difference between the carteolol group and the control group(P>0.05).The m RNA expression level of 5’-Nase in the latanoprost group was also significantly higher than carteolol group(F=71.169 P<0.005)and control group(P<0.005).The conjunctival lymphatics were positive immunofluorescence stained with the 5’-Nase antibodies in the latanoprost group and not stained in the control group.CONCLUSION:Latanoprost eye drops can induce conjunctival lymphangiogenesis which may be concerned in clinical implications.

Comparison of Efficacy and Safety Evaluation of Latanoprost Formulations with and without Benzalkonium Chloride

Background: This study investigated the safety (cytotoxicity in vitro) and pharmacological effects (ocular hypotensive effects and aqueous humor concentrations in normotensive monkeys in vivo) of latanoprost formulations with benzalkonium chloride (latanoprost with BAK) and without BAK (NP). Methods: A bioequivalence study of latanoprost with BAK and NP was also conducted on human healthy volunteers. Cytotoxicity and the protective effect against H2O2 stress in vitro were evaluated using human corneal epithelial cells. The ocular hypotensive effects in normotensive monkeys were measured by pneumatonometer and the aqueous humor concentrations of latanoprost free acid were determined by liquid chromatography/mass spectrum (LC/MS) methods. The bioequivalence study of latanoprost with BAK and NP was carried out as a single eye drop, two-sequence, crossover randomized study. Results: Cytotoxicity tests in vitro revealed that NP was less toxic than latanoprost with BAK and significantly inhibited H2O2 induced cell damage while latanoprost with BAK did not. The hypotensive efficacy and the latanoprost free acid concentrations in aqueous humor of each formulation were not significantly different in monkeys. In the bioequivalence study, NP was bioequivalent to latanoprost with BAK. NP was safer than latanoprost with BAK with respect the results obtained in the in vitro cytotoxicity test. There was no difference observed between latanoprost with BAK and NP in the IOP lowering effect in monkeys and healthy volunteers. Conclusion: Taken together, these results indicate that NP is as effective as latanoprost with BAK, and is more likely to maintain ocular surface health than latanoprost with BAK.

latanoprost与噻吗心安治疗开角型青光眼及高眼压症的临床对照研究

目的 验证latanoprost对青光眼的治疗价值。方法 对 12 8例原发性开角型青光眼和高眼压症患者进行为期 12周的多中心、开放式、临床随机对照研究 ,观察其降眼压疗效和不良反应。分别应用 0 0 0 5 %latanoprost每日滴眼 1次及 0 5 %噻吗心安每日滴眼 2次。随访时间为治疗前、治疗后 2、6及 12周 ,测量眼压并观察记录局部、全身不良反应。结果 共入选 12 8例 (latanoprost组 6 3例 ,噻吗心安组 6 5例 ) ,其中 117例 (latanoprost组 6 0例 ,噻吗心安组 5 7例 )做有效性评估。latanoprost组平均眼压下降值为 (7 5± 0 3)mmHg(1mmHg=0 133kPa) (32 % ,t=2 2 73,P <0 0 0 0 1) ;噻吗心安组为 (6 1± 0 3)mmHg (2 6 % ,t=17 94,P <0 0 0 0 1)。两组之差 1 4mmHg (F =9 5 4,P =0 0 0 2 6 )。噻吗心安组 2例因眼压控制不良退出研究 ,latanoprost组无因眼压控制不良而退出者。latanoprost组 3例有眼部异物感 ,1例睫毛变黑、变长 ,未发现其他与药物有关的眼部和全身不良反应。结论latanoprost的降眼压疗效优于噻吗心安 。

Latanoprost及Unoprostone对兔及猴葡萄膜MMP-2表达影响的研究

研究 PGF2α类抗青光眼药 L atanoprost和 Unoprostone对兔及猴的降眼压途径有否不同。方法 :1.用 0 .0 0 5 % L atanoprost、 0 .12 % U noprostone分别对 12只兔、 8只猴点眼 10天 ,测量点眼前后兔及猴眼压 ,兔眼前房水蛋白浓度。 2 .采用 Zymography技术对兔、猴点眼后葡萄膜中 MMP- 2活性进行定量分析。结果 :1L atanoprost及 Unoproston都可有效降低兔及猴眼压 ,并且对兔眼前房水蛋白浓度无明显影响。 2两种药物点眼后 ,猴葡萄膜中 MMP- 2活性增强 ,却对兔葡萄膜中 MMP- 2活性均无明显影响。结论 :L atanoprost及 Unoprostone对猴的降眼压作用机制在于影响了葡萄膜巩膜房水流出 。

拉坦前列素联合布林佐胺治疗青光眼的效果观察

目的 观察拉坦前列素联合布林佐胺治疗青光眼的临床效果。方法 选取2021年2月至2022年1月我院收治的122例青光眼患者,随机分为对照组(n=61)和观察组(n=61),均为单眼发病。对照组给予布林佐胺滴眼液治疗,观察组在对照组基础上给予拉坦前列素滴眼液治疗。比较两组患者的治疗效果、视力、眼压及不良反应。结果 观察组治疗总有效率为93.44%,明显高于对照组的80.33%(P <0.05)。治疗前,两组的视力、眼压比较差异无统计学意义(P>0.05);治疗后,两组的视力、眼压均有所改善,且观察组视力、眼压明显优于对照组(P <0.05)。治疗期间,观察组不良反应发生率为16.39%,与对照组的13.11%比较差异无统计学意义(P>0.05)。结论 拉坦前列素联合布林佐胺治疗青光眼效果显著,可明显改善患者眼压与视力,且安全可靠,值得临床推广应用。

推拿促进房水内源性前列腺素的生成调节大鼠睫状体淋巴管增生

目的:探讨推拿促进大鼠眼内前列腺素的生成,诱导大鼠眼部睫状体内淋巴管的增生,进而降低青光眼眼压的作用机制。方法:将48只SD大鼠造模后随机分为青光眼模型组、推拿组、拉坦前列腺素组和推拿结合拉坦前列腺素组,每组12例。治疗过程中分别抽取各组不同时间段房水进行酶联免疫吸附试验(ELISA),采用蛋白质印迹法、定量聚合酶链反应、免疫荧光法、免疫组织化学法检测同源盒基因转录因子1(Prox-1)、5′-核苷酸酶(5′-Nase)表达水平,淋巴管酶组织化学染色法检测各组睫状体内淋巴管的增生情况。结果:推拿结合拉坦前列腺素组眼压均低于其他组(P<0.05);推拿结合拉坦前列腺素组中Prox-1、5′-Nase表达水平均高于其他组(P<0.05);推拿结合拉坦前列腺素组睫状体组织淋巴增殖均高于其他组。结论:推拿可以有效促进睫状体淋巴管的增生,而增生的淋巴管能吸收多余的房水导致眼压下降。

通窍明目汤联合拉坦前列腺素对原发性开角型青光眼患者血流动力学的影响

目的分析通窍明目汤与拉坦前列腺素对原发性开角型青光眼(POAG)患者血流动力学的影响。方法选择2019年1月至2021年3月许昌医院94例POAG患者,采用抽签法分为两组,各47例。对照组使用拉坦前列素滴眼液治疗,观察组使用通窍明目汤联合拉坦前列素滴眼液治疗,两组均治疗6周。比较两组临床疗效、治疗前后眼部血流动力学指标及眼压、视力,观察两组治疗期间不良反应发生率。结果观察组治疗6周时的总有效率较对照组高(P<0.05)。治疗6周,两组眼底视网膜中央动脉的收缩期峰值血流速度(PSV)、舒张末期血流速度(EDV)均增大,且观察组更大(P<0.05);两组血管阻力指数(RI)均减小,且观察组更小(P<0.05);两组眼压均降低,且观察组更低,两组视力均升高,且观察组更高(P<0.05);两组不良反应发生率比较差异无统计学意义(P>0.05)。结论通窍明目汤与拉坦前列腺素治疗POAG的效果确切,可改善患者眼部血流动力学,降低眼压,改善视力,且不良反应较少。

贝美前列素对比拉坦前列素治疗青光眼有效性与安全性的Meta分析

目的比较贝美前列素与拉坦前列素治疗青光眼的有效性和安全性,为临床合理用药提供循证参考。方法计算机检索PubMed、Embase、the Cochrane Library、中国生物医学文献数据库、中国知网、万方数据、维普网,检索时限均为建库起至2022年3月。收集贝美前列素(试验组)对比拉坦前列素(对照组)治疗青光眼的随机对照试验(RCT),筛选文献、提取资料后,采用Cochrane系统评价员手册5.1.0推荐的偏倚风险评估工具对纳入文献的质量进行评价,采用RevMan 5.4和Stata 12软件进行Meta分析、敏感性分析和发表偏倚分析。结果共纳入19项RCT,共计2181例患者。Meta分析结果显示,试验组患者的终点眼压下降值(IOPR)[MD=0.89,95%CI(0.53,1.25),P<0.00001]显著低于对照组,结膜充血发生率[RR=1.89,95%CI(1.59,2.24),P<0.00001]、睫毛增长发生率[RR=3.17,95%CI(1.97,5.08),P<0.00001]均显著高于对照组;两组患者的眼睛刺激/异物感、瘙痒、眼干、眼部炎症、眼痛、视觉障碍、虹膜/皮肤色素沉着发生率比较,差异均无统计学意义(P>0.05)。按不同用药时间节点进行的亚组分析结果显示,试验组患者用药1、3、6个月时的IOPR均显著低于对照组(P<0.05)。敏感性分析结果显示,本研究结果稳健。发表偏倚分析结果显示,本研究存在发表偏倚的可能性较小。结论与拉坦前列素比较,贝美前列素在改善眼内压方面效果更优,但结膜充血和睫毛增长的发生风险较高。

青光眼用药的临床效果分析

目的探究青光眼用药的临床效果。方法94例青光眼患者,依照随机数字表法分为对照组与试验组,每组47例。对照组使用拉坦前列素滴眼液治疗,试验组采用布林佐胺滴眼液治疗。对比两组不良反应发生率、生活质量评分、治疗效果及治疗前后眼压、心理状态评分。结果试验组不良反应发生率0明显低于对照组的12.77%,差异具有统计学意义(P<0.05)。试验组躯体功能、心理功能、社会功能、物质生活状态评分均高于对照组,差异具有统计学意义(P<0.05)。试验组总有效率95.74%高于对照组的68.09%,差异具有统计学意义(P<0.05)。治疗后,试验组眼压为(17.24±1.26)mm Hg(1 mm Hg=0.133 kPa),低于对照组的(22.99±1.79)mm Hg,差异具有统计学意义(P<0.05)。治疗后,对照组焦虑自评量表(SAS)评分与抑郁自评量表(SDS)评分分别为(46.58±2.89)、(46.56±2.50)分,试验组分别为(44.87±2.10)、(44.87±2.16)分。治疗后,试验组SAS评分与SDS评分明显低于对照组,差异具有统计学意义(P<0.05)。结论青光眼患者采用布林佐胺滴眼液治疗更具有临床意义,可稳定控制患者的眼压,提升治疗效果,极大改善患者的生理与心理状态,为青光眼的治疗奠定了坚实的基础,适合在临床上进行大范围推广。

拉坦前列素滴眼液联合他克莫司软膏、308 nm准分子光治疗稳定期毛发部位白癜风疗效观察

目的探讨0.005%拉坦前列素滴眼液联合0.1%他克莫司软膏、308 nm准分子光治疗稳定期毛发部位白癜风的效果。方法选取2020年5月至2022年5月期间江西省皮肤病专科医院白癜风门诊收治的60例稳定期毛发部位白癜风患者随机分为两组,每组各30例。对照组予以0.1%他克莫司软膏+308 nm准分子光治疗,观察组予以0.005%拉坦前列素滴眼液+0.1%他克莫司软膏+308 nm准分子光治疗,均连续治疗16周。比较两组治疗4、8、12、16周时临床疗效及治疗期间不良反应。结果治疗4周时两组临床总有效率比较,差异无统计学意义(P>0.05);观察组治疗8、12、16周时临床总有效率分别为53.33%、60.00%、70.00%,高于对照组的26.67%、33.33%、43.33%,差异有统计学意义(P<0.05);观察组不良反应发生率为20.00%,对照组不良反应发生率为13.33%,差异无统计学意义(P>0.05)。结论稳定期毛发部位白癜风患者应用0.005%拉坦前列素滴眼液联合0.1%他克莫司软膏、308 nm准分子光治疗取得良好的效果,且安全性好,值得推广。

国产拉坦前列腺素治疗开角型青光眼和高眼压症的疗效及安全性

目的:观察国产拉坦前列腺素滴眼液(见康)治疗开角型青光眼和高眼压症的临床疗效及安全性。方法:采用随机、单盲对照研究。原发性开角型青光眼或高眼压症的患者90例随机分三组,试验组:国产0.05g/L拉坦前列腺素(见康);对照组1:进口0.05g/L拉坦前列腺素(适利达);对照组2:0.04g/L曲伏前列素(苏为坦),每组30例患者。三组患者均9:00pm给药1次,疗程4wk。结果:用药2wk后,三组间治疗后眼压差异无统计学意义(P=0.673)。治疗4wk后,三组日眼压曲线各时间点眼压下降值差异无统计学意义。三组病例中均有轻度结膜充血的患者,试验组4例(13%),对照组1:3例(10%),对照组2:8例(27%)。结论:国产拉坦前列素滴眼液(见康)可有效降低眼压,安全性好,为治疗开角型青光眼及高眼压症提供了新的选择。

前列腺素衍生物拉坦前列素(适利达)与噻吗心安治疗青光眼的临床对比研究

目的 :验证前列腺素衍生物拉坦前列素 (适利达 )治疗青光眼的临床疗效和安全性。方法 :采用双盲、随机对照的方法 ,对46例原发性开角型青光眼和高眼压症患者进行为期12周的研究 ,观察其降眼压疗效和不良反应。用0 005 %拉坦前列素每日滴眼1次与0 5 %噻吗心安每日滴眼2次进行随机对比。治疗前 ,治疗后2周、6周及12周随访 ,测量眼压并观察眼局部及全身不良反应。结果 :在入选的46例患者中 (拉坦前列素组22例 ,噻吗心安组24例 ) ,拉坦前列素组平均眼压下降值为 (7 86±2 39)mmHg(下降31 1 % ,P<0 001) ;噻吗心安组为 (6 24±2 58)mmHg(下降24 9 % ,P<0 001)。两组之差1 62mmHg(P<0 01)。拉坦前列素组2例有眼部异物感及充血 ,未发现其他与药物有关的眼部和全身不良反应。结论 :拉坦前列素的降眼压疗效优于噻吗心安 ,且无明显毒、副作用 ,1天仅用1次 ,是理想的抗青光眼药物。